| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10763687 | Biochemical and Biophysical Research Communications | 2011 | 6 Pages |
Abstract
⺠Xanomeline has proven therapeutic effect in Alzheimer's disease patients, but caused so many adverse effects that its development was stopped. ⺠EUK1001, a fluorinated derivative of xanomeline, has greater affinity for M1 mAChRs and significantly less side effects than xanomeline. ⺠We explored the effects of EUK1001 and xanomeline in AD-like presenilin 1/presenilin 2 conditional double knockout (PS cDKO) mice. ⺠EUK1001 improved recognition memory deficits, ameliorated brain atrophy, and suppressed elevation of brain tau phosphorylation in PS cDKO mice. ⺠EUK1001 had advantages over xanomeline in most therapeutically relevant effects in PS cDKO mice.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Dong Wang, Liguo Yang, Jingjing Su, Yan Niu, Xiaoping Lei, Juan Xiong, Xiaohua Cao, Yinghe Hu, Bing Mei, Jin-Feng Hu,